Shire Says Vpriv Is A Viable Option for Cerezyme Patients; Gets PDUFA For Firazyr
This article was originally published in The Pink Sheet Daily
Executive Summary
Firazyr could enjoy a dosing advantage over other HAE drugs currently on the U.S. marketplace if it can get approval from FDA.